Consensus BioCryst Pharmaceuticals, Inc.

Equities

BCRX

US09058V1035

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-17 pm EDT			5-day change	1st Jan Change
4.58 ^USD	-0.65%		-5.95%	-23.54%

Apr. 17	BioCryst Pharmaceuticals Secures Approval for Orladeyo in Brazil	MT
Apr. 17	BioCryst Pharmaceuticals, Inc. Announces Approval of ORLADEYO (berotralstat) by the Brazilian Health Regulatory Agency	CI

Evolution of the average Target Price on BioCryst Pharmaceuticals, Inc.

Price target over the last 5 years

History of analyst recommendation changes

7e1f.Y9DiM9V5UwRtVb0PbDYHtbbrlyKdrcJb-W4szoZ50_4.KpiTe-IvJ1UZOs5CPl9ojPKyxRTCx_Btnj1J9vZOi8sPpIcEglQ9SCIz6A~6bfa17cf50eb64a553379c2d6eeff50d

Analyst Recommendations on BioCryst Pharmaceuticals, Inc.

BioCryst Pharmaceuticals, Inc. Presents New Real-World Data Showing Reduced Attack Rates in Patients with HAE with Normal C1-Inhibitor Following Long-Term Treatment with ORLADEYO(R) (berotralstat)	Nov. 10	CI
BioCryst Pharmaceuticals Receives Upgrade From RBC to Outperform From Sector Perform, Price Target Raised to $10 From $9	23-09-18	MT
Jefferies Upgrades BioCryst Pharmaceuticals to Buy From Hold, Price Target is $11	23-08-04	MT
RBC Raises Price Target on BioCryst Pharmaceuticals to $9 From $8, Keeps Sector Perform, Speculative Risk	23-08-04	MT
BofA Securities Upgrades BioCryst Pharmaceuticals to Buy From Neutral, Price Target is $10	23-07-13	MT
RBC Trims BioCryst Pharmaceuticals' Price Target to $8 From $9, Keeps Sector Perform Speculative Risk Rating	23-07-07	MT
Evercore ISI Lowers Price Target on BioCryst Pharmaceuticals to $10 From $13, Maintains Outperform Rating	23-04-20	MT
RBC Capital Adjusts BioCryst Pharmaceuticals Price Target to $9 From $10, Maintains Sector Perform - Speculative Risk Rating	23-04-06	MT
Biocryst Presents New Long-Term and Real-World Data Demonstrating Sustained Reductions in Hereditary Angioedema Attack Rates and Improvement in Quality of Life with Orladeyo® (Berotralstat)	23-02-24	CI
Needham Upgrades BioCryst Pharmaceuticals to Buy From Hold With $14 Price Target	23-02-22	MT
RBC Adjusts Price Target on BioCryst Pharmaceuticals to $10 From $12, Maintains Sector Perform Rating	23-02-22	MT
Biocryst Presents Real-World Data Showing Rapid and Sustained Hae Attack Rate Reduction After Beginning Orladeyo® (Berotralstat), Regardless of Prior Prophylactic Therapy	22-11-10	CI
Evercore ISI Upgrades BioCryst Pharmaceuticals to Outperform From In Line With $16 Price Target	22-11-02	MT
RBC Trims BioCryst Pharmaceuticals' Price Target to $13 From $14 on Revised Estimates, Keeps Sector Perform Rating, Speculative Risk Qualifier	22-11-02	MT
Oppenheimer Downgrades BioCryst Pharmaceuticals to Perform From Outperform, Removes $13 Price Target	22-08-05	MT
Barclays Adjusts Price Target on BioCryst Pharmaceuticals to $14 From $12, Keeps Equalweight Rating	22-08-05	MT
Evercore ISI Downgrades BioCryst Pharmaceuticals to In-Line From Outperform; Price Target is $14	22-08-05	MT
BioCryst Pharmaceuticals, Inc. Presents New Data Demonstrating Consistently Low Attack Rates Among HAE Patients After Switching to ORLADEYO® (berotralstat)	22-07-01	CI
Oppenheimer Adjusts BioCryst Pharmaceuticals Price Target to $13 From $16, Maintains Outperform Rating	22-05-12	MT
Jefferies Lowers Price Target for BioCryst Pharmaceuticals to $11 From $18, Maintains Hold Rating	22-05-06	MT
Piper Sandler Adjusts Price Target on BioCryst Pharmaceuticals to $19 From $24, Reiterates Overweight Rating	22-05-06	MT
RBC Cuts Price Target on BioCryst Pharmaceuticals to $13 From $14, Maintains Sector Perform-Speculative Risk Rating	22-05-06	MT
Barclays Downgrades BioCryst Pharmaceuticals to Equalweight From Overweight, Reduces Price Target to $13 From $22	22-04-18	MT
RBC Cuts Price Target on BioCryst Pharmaceuticals to $14 From $16, Noting 'Uncertain' Viability for '9930; Sector Perform-Speculative Risk Kept	22-04-12	MT
RBC Capital Lowers Price Target for BioCryst Pharmaceuticals to $14 From $16, Maintains Sector Perform Rating	22-04-11	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

4.58 USD

Average target price

12.2 USD

Spread / Average Target

+166.38%

High Price Target

20 USD

Spread / Highest target

+336.68%

Low Price Target

6 USD

Spread / Lowest Target

+31.00%

Consensus detail

Consensus revision (last 18 months)

Analysts covering BioCryst Pharmaceuticals, Inc.

RBC Capital Markets
Jefferies & Co.
BofA Securities
Evercore ISI
Needham & Co.
Barclays
Oppenheimer
Piper Sandler
JPMorgan Chase
Cantor Fitzgerald
HC Wainwright
Cowen

Ratings for BioCryst Pharmaceuticals, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar